59.28 -0.07 (-0.12%)
After hours: 5:33PM EST
|Bid||59.03 x 800|
|Ask||60.20 x 900|
|Day's Range||58.66 - 59.37|
|52 Week Range||41.03 - 60.69|
|Beta (5Y Monthly)||1.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 06, 2020 - May 10, 2020|
|Forward Dividend & Yield||1.92 (3.23%)|
|Ex-Dividend Date||Mar 30, 2020|
|1y Target Est||58.43|
Leading drug distributor stocks remain sensitive to ongoing opioid settlement negotiations. Here are crucial technical levels to watch.
Twenty one states reject an $18 billion settlement offer from three major drug distributors to resolve litigation over their alleged role in the opioid crisis, the Wall Street Journal reported on Friday, citing a letter sent to the companies' law firms earlier this week. The dissenting states want the companies - AmeriSourceBergen Corp, McKesson Corp and Cardinal Health Inc - to pay between $22 billion and $32 billion, WSJ reported https://on.wsj.com/37kSRkA, citing a person familiar with a matter. McKesson is focused on finalizing a global settlement structure that would provide billions of dollars in immediate funding and relief to states and local communities, a company spokesman said in an emailed statement.
Shares of drug wholesalers, who have held talks to settle opioid litigation, sank in morning trading Friday, after The Wall Street Journal reported that 21 states had rejected an $18 billion settlement offer. Shares of AmerisourceBergen Corp. dropped 2.4%, Cardinal Health Inc. shed 2.5%, McKesson Corp. lost 1.4% and Johnson & Johnson fell 0.4%. In comparsion, the S&P 500 inched up less than 0.1%. The WSJ report, which cited a person familiar with the matter, said the dissenting states want the wholesalers to pay between $22 billion and $32 billion, for their alleged roles in contributing to the opioid crisis.
The Cardinal Health (NYSE: CAH) board of directors today approved a quarterly dividend of $0.4811 per share. The dividend will be payable on April 15, 2020, to shareholders of record at the close of business on April 1, 2020.
Coronavirus is ravaging China and several other countries. With no cure yet, health officials are struggling to stop its spread. Demand for medical supplies like masks is up manifold.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cardinal Health (CAH) fiscal second-quarter results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.
Cardinal (CAH) delivered earnings and revenue surprises of 25.62% and 0.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Dividend paying stocks like Cardinal Health, Inc. (NYSE:CAH) tend to be popular with investors, and for good reason...
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
Cardinal Health (CAH) fiscal second-quarter earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.
Today, in continued coordination with the U.S. Food and Drug Administration (FDA), Cardinal Health announced it is initiating two voluntary field actions for select Cardinal Health Presource® Procedure Packs containing gowns that were part of last week's recall of AAMI Level 3 surgical gowns. These procedure packs, also known as kits, had been placed on voluntary hold at the time of the gown recall.